Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.
Indication: KRAS NP_004976.2:p.G12D
Modality: cell therapy
Target: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Sponsor: M.D. Anderson Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
View original source fields
Condition raw: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Condition normalized: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Target normalized: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA